<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1939">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05135923</url>
  </required_header>
  <id_info>
    <org_study_id>20/02822</org_study_id>
    <nct_id>NCT05135923</nct_id>
  </id_info>
  <brief_title>Glutenfree, Gut Microbiota and Metabolic Regulation</brief_title>
  <acronym>GRAIN</acronym>
  <official_title>The Effect of Gluten-free Diet on Gut Microbiota and Metabolic Regulation in People With Coeliac Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo Metropolitan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Det Glutenfrie Verksted</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo Metropolitan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High intake of dietary fiber provides health benefits and reduces the risk of developing&#xD;
      cardio-metabolic diseases, such as type 2 diabetes (T2D) and cardiovascular disease (CVD).&#xD;
      The intake of fiber is below the recommendations worldwide. In Norway, bread and cereals&#xD;
      represent a major source of fiber. A low fiber intake is evident for people with celiac&#xD;
      disease due to the removal of wheat, rye and barley from the diet. We therefore need to&#xD;
      increase our knowledge in relation to fiber-rich food that will be tolerated also by people&#xD;
      with celiac disease. The aim of the study is to investigate the effect of fiber rich gluten&#xD;
      free products on blood glucose levels compared to benchmark gluten free products.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of blood glucose</measure>
    <time_frame>3 weeks</time_frame>
    <description>Blood analyses of glucose (fasting and post-prandial (after an OGTT)) before and after intervention with benchmark versus optimized gluten-free products.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of blood cholesterol, triglycerides, fatty acids, C-peptide</measure>
    <time_frame>3 weeks</time_frame>
    <description>Blood analyses of total cholesterol, triglycerides, fatty acids, and C-peptide (fasting) before and after intervention with benchmark versus optimized gluten-free products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of blood inflammatory markers</measure>
    <time_frame>3 weeks</time_frame>
    <description>Blood analyses of inflammatory markers (fasting) before and after intervention with benchmark versus optimized gluten-free products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feces microbiota analyses performed with Bio-Me's Precision Microbiome Profiling platform (PMP)</measure>
    <time_frame>3 weeks</time_frame>
    <description>Feces analyses of microbiota before and after intervention with benchmark versus optimized gluten-free products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Symptoms Rating Scale-Irritable bowl syndrome (GSRS-IBS)</measure>
    <time_frame>3 weeks</time_frame>
    <description>GSRS-IBS analyses before and after intervention with benchmark versus optimized gluten-free products with the following response scale: 1 (no discomfort at all) to 7 (very severe discomfort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of satiety hormones in blood</measure>
    <time_frame>3 weeks</time_frame>
    <description>Blood analyses of satiety hormones (fasting) before and after intervention with benchmark versus optimized gluten-free products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bristol Stool Chart (BSC)</measure>
    <time_frame>3 weeks</time_frame>
    <description>BSC analyses before and after intervention with benchmark versus optimized gluten-free products with a scale from 1 (separate hard lumps, like nuts) to 7 (watery, no solid pieces).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>Benchmark gluten-free products</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Products containing less than 6g fibre per 100g product.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimised gluten-free products</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Products containing less than 6g fibre per 100g product.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Randomized, controlled trial (RCT) with parallel arms and double blinded</intervention_name>
    <description>Experiment group receive optimized gluten free products (high in fiber and whole grain) compared to comparable benchmark gluten free products (control group).</description>
    <arm_group_label>Benchmark gluten-free products</arm_group_label>
    <arm_group_label>Optimised gluten-free products</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy individuals with celiac disease&#xD;
&#xD;
          -  BMI 18.5-27&#xD;
&#xD;
          -  18-65 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic metabolic diseases, such as diabetes (type 1 and 2), cardiovascular diseases,&#xD;
             cancer the last six months&#xD;
&#xD;
          -  gut diseases, including chron's disease, ulcerative colite&#xD;
&#xD;
          -  food allergies or intolerance, except for coliac disease&#xD;
&#xD;
          -  pregnant and/or lactating&#xD;
&#xD;
          -  smokers&#xD;
&#xD;
          -  BMI &lt;18.5 and &gt;27&#xD;
&#xD;
          -  planned weight reduction and/or 5% weight change the last three months&#xD;
&#xD;
          -  blood donor the last two months and during the study period&#xD;
&#xD;
          -  not willing to stop using dietary supplements, including probiotic products, cod liver&#xD;
             oil etc, four weeks before and throughout the study&#xD;
&#xD;
          -  use of antibiotics &lt; three months before study start and throughout the study period&#xD;
&#xD;
          -  alcohol consume &gt; 40 g/day&#xD;
&#xD;
          -  hormone treatment (except for contraceptives)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vibeke H Telle-Hansen, PhD</last_name>
    <phone>+4793048873</phone>
    <email>vtelle@oslomet.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mari Myhrstad, PhD</last_name>
    <phone>+4791392176</phone>
    <email>mmyhrsta@oslomet.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo Metropolitan University</name>
      <address>
        <city>Oslo</city>
        <zip>0130</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vibeke Telle-Hansen, PhD</last_name>
      <phone>47 67 23 68 19</phone>
      <email>vtelle@oslomet.no</email>
    </contact>
    <investigator>
      <last_name>Vibeke Telle-Hansen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo Metropolitan University</investigator_affiliation>
    <investigator_full_name>Vibeke Telle-Hansen</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

